Podchaser Logo
Home
MDMA & Psilocybin Improve PTSD & Depression Via Similar Brain Mechanisms? Psychedelic Effect Needed? || NeuroBeer Clips

MDMA & Psilocybin Improve PTSD & Depression Via Similar Brain Mechanisms? Psychedelic Effect Needed? || NeuroBeer Clips

Released Tuesday, 4th August 2020
Good episode? Give it some love!
MDMA & Psilocybin Improve PTSD & Depression Via Similar Brain Mechanisms? Psychedelic Effect Needed? || NeuroBeer Clips

MDMA & Psilocybin Improve PTSD & Depression Via Similar Brain Mechanisms? Psychedelic Effect Needed? || NeuroBeer Clips

MDMA & Psilocybin Improve PTSD & Depression Via Similar Brain Mechanisms? Psychedelic Effect Needed? || NeuroBeer Clips

MDMA & Psilocybin Improve PTSD & Depression Via Similar Brain Mechanisms? Psychedelic Effect Needed? || NeuroBeer Clips

Tuesday, 4th August 2020
Good episode? Give it some love!
Rate Episode

#neuroscience #psilocybin #MDMA #depression #psychedelicmedicine From NeuroBeer #4 - streamed live June 15, 2020. Full conversation: https://youtu.be/yhxyuBLiLs8 

Do you need to have a psychedelic trip to experience the beneficial therapeutic actions of psychedelics? How long does it take for psychedelic drugs like MDMA or magic mushrooms (psilocybin) to have therapeutic effects for depression or ptsd treatment? How long do these antidepressant actions of MDMA & psilocybin last? And How do these psychedelic drugs produce their beneficial effects in the brain to begin with? Serotonin receptors vs metabotropic glutamate receptors involved? 

These highly anticipated results follow-up with patients treated with MDMA-assisted psychotherapy 1+ years after treatment to evaluate how long the benefits last for.  These freshly published results are derived from six separate phase 2 clinical trials that were published June 3rd in the journal Psychopharmacology.

We're a group of Canadian neuroscientists reviewing the latest news, events and scholarly publications from this week in neuroscience and beyond! In each NeuroDrugs live stream we review classics in the field of addiction neuroscience, as well as newly published articles on a weekly basis. 

In this clip we comment on the recent phase-2 follow up studies from the Multidisciplinary Association For Psychedelic Studies (MAPS). In September 2019 the first results from pooled analyses of 6 double blinded and randomized studies assessing MDMA for PTSD management entitled, "Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline". More than 1 year has passed since the initial trials were completed, and in June 2020 the  results from the 1+ year follow up study of these same individuals were reported. We explore these results and possible mechanisms underlying MDMA and psilocybin assisted psychotherapy for depression and ptsd. 

open access article phase-2 follow up study: https://link.springer.com/article/10.1007/s00213-020-05548-2 

Original Phase 2 pooled analysis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751381/ 

Additional resources from MAPS: https://maps.org/research/mdma/ptsd/phase3&https://maps.org/research/mdma/mdma-research-timeline

Join us for NeuroBeer every Monday (8pm EDT) & NeuroDrugs every Wednesday (9pm EDT) on YouTube for the largest interactive live streaming journal club & contribute to the conversation! Stay tuned to stay up to date with the latest in neuroscience / general science news! 

A Production of First-Person Science

Please subscribe @ www.youtube.com/firstpersonsciencepodcast if you enjoy our content, and share it with friend and platforms that might be interested! It goes a long way in helping us stamp out misinformation in neuroscience media! 

 

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features